Diarrheal-associated gut dysbiosis in cancer and inflammatory bowel disease patients is exacerbated by Clostridioides difficile infection

Frontiers in Cellular and Infection Microbiology

Cellular and Infection Microbiology

Edyta Waker¹  Maria Kulecka²  Natalia Zeber-Lubecka²  Jerzy Ostrowski²  Michał Mikula³  Michalina Dąbrowska³  Magdalena Piątkowska³  Katarzyna Bagińska³  Aneta Bałabas³  Maria Głowienka³  Anna Kluska³  Paweł Czarnowski⁴ 

[1] Department of Clinical Microbiology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland;Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, Warsaw, Poland;Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland;Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland;Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland;Department of Biochemistry, Radioimmunology and Experimental Medicine, The Children’s Memorial Health Institute, Warsaw, Poland;

关键词: diarrhea;    gut dysbiosis;    inflammatory bowel disease;    Clostridioides difficile;    microbiome;    metabolites;    CDI;   

DOI  :  10.3389/fcimb.2023.1190910

 received in 2023-03-21, accepted in 2023-07-03,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionLow diversity gut dysbiosis can take different forms depending on the disease context. In this study, we used shotgun metagenomic sequencing and gas chromatography–mass spectrometry (GC-MS) to compared the metagenomic and metabolomic profiles of Clostridioides (Clostridium) difficile diarrheal cancer and inflammatory bowel disease (IBD) patients and defined the additive effect of C. difficile infection (CDI) on intestinal dysbiosis.ResultsThe study cohort consisted of 138 case-mix cancer patients, 43 IBD patients, and 45 healthy control individuals. Thirty-three patients were also infected with C. difficile. In the control group, three well-known enterotypes were identified, while the other groups presented with an additional Escherichia-driven enterotype. Bacterial diversity was significantly lower in all groups than in healthy controls, while the highest level of bacterial species richness was observed in cancer patients. Fifty-six bacterial species had abundance levels that differentiated diarrheal patient groups from the control group. Of these species, 52 and 4 (Bacteroides fragilis, Escherichia coli, Klebsiella pneumoniae, and Ruminococcus gnavus) were under-represented and over-represented, respectively, in all diarrheal patient groups. The relative abundances of propionate and butyrate were significantly lower in fecal samples from IBD and CDI patients than in control samples. Isobutyrate, propanate, and butyrate concentrations were lower in cancer, IBD, and CDI samples, respectively. Glycine and valine amino acids were over- represented in diarrheal patients.ConclusionOur data indicate that different external and internal factors drive comparable profiles of low diversity dysbiosis. While diarrheal-related low diversity dysbiosis may be a consequence of systemic cancer therapy, a similar phenotype is observed in cases of moderate to severe IBD, and in both cases, dysbiosis is exacerbated by incidence of CDI.

【 授权许可】

Unknown   
Copyright © 2023 Kulecka, Zeber-Lubecka, Bałabas, Czarnowski, Bagińska, Głowienka, Kluska, Piątkowska, Dąbrowska, Waker, Mikula and Ostrowski